| Dr Samantha Morgan Bandremer, MD | |
|
877 Stewart Ave Ste 7, Garden City, NY 11530-4803 | |
| (516) 222-0722 | |
| Not Available |
| Full Name | Dr Samantha Morgan Bandremer |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 877 Stewart Ave Ste 7, Garden City, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245894864 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 323974 (New York) | Primary |
| Entity Name | North Shore-lij Ob-gyn At Garden City Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780022772 PECOS PAC ID: 5294978516 Enrollment ID: O20130905000207 |
News Archive
A new reversible blood thinner for angioplasty patients wasn't superior over placebo for its primary combined endpoint of heart attack, all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.
The U.S. Department of Health and Human Services (HHS) and the U.S. Environmental Protection Agency (EPA) today are announcing important steps to ensure that standards and guidelines on fluoride in drinking water continue to provide the maximum protection to the American people to support good dental health, especially in children.
There is no association between access to federally qualified health centers and emergency department visits for either uninsured or Medicaid-insured patients. That is the conclusion of a study to be published in the February 2019 issue of Academic Emergency Medicine, a journal of the Society for Academic Emergency Medicine.
Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.
Colorectal cancer is the third most common form of cancer and the second most common cause of cancer deaths in the United States. The chance of developing colorectal cancer increases with age. Now, a study by University of Missouri School of Medicine researchers shows that minority and ethnic groups are being diagnosed with colorectal cancer at younger ages and more advanced stages than non-Hispanic whites.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Samantha Morgan Bandremer, MD 4101 N Ocean Blvd Apt D809, Boca Raton, FL 33431-5314 Ph: (561) 512-6608 | Dr Samantha Morgan Bandremer, MD 877 Stewart Ave Ste 7, Garden City, NY 11530-4803 Ph: (516) 222-0722 |
News Archive
A new reversible blood thinner for angioplasty patients wasn't superior over placebo for its primary combined endpoint of heart attack, all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.
The U.S. Department of Health and Human Services (HHS) and the U.S. Environmental Protection Agency (EPA) today are announcing important steps to ensure that standards and guidelines on fluoride in drinking water continue to provide the maximum protection to the American people to support good dental health, especially in children.
There is no association between access to federally qualified health centers and emergency department visits for either uninsured or Medicaid-insured patients. That is the conclusion of a study to be published in the February 2019 issue of Academic Emergency Medicine, a journal of the Society for Academic Emergency Medicine.
Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.
Colorectal cancer is the third most common form of cancer and the second most common cause of cancer deaths in the United States. The chance of developing colorectal cancer increases with age. Now, a study by University of Missouri School of Medicine researchers shows that minority and ethnic groups are being diagnosed with colorectal cancer at younger ages and more advanced stages than non-Hispanic whites.
› Verified 7 days ago
Miss Kayla Rose Branca, PA Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 520 Franklin Ave, Garden City, NY 11530 Phone: 516-464-5308 | |
Alexander D. Kofinas, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 901 Stewart Ave Ste 245, Garden City, NY 11530 Phone: 516-832-0300 Fax: 516-832-0301 | |
John L Gomes, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1000 Franklin Ave, Suite 200, Garden City, NY 11530 Phone: 516-222-8883 Fax: 516-222-7091 | |
Shira M Feinstein, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1000 Zeckendorf Blvd, Garden City, NY 11530 Phone: 516-542-6880 Fax: 516-542-5556 | |
Mrs. Patricia Keegan-smith, FNP Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 877 Stewart Ave Ste 3, Garden City, NY 11530 Phone: 516-987-9216 | |
Alisha Tanvir Sial, PA Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 200 Garden City Plz, Garden City, NY 11530 Phone: 516-663-6400 Fax: 516-307-8840 | |
Gary S Rosenberg, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 877 Stewart Ave, Suite 7, Garden City, NY 11530 Phone: 516-222-0722 Fax: 516-683-0184 |